Hoth Therapeutics Yönetim

Yönetim kriter kontrolleri 3/4

Hoth Therapeutics CEO'su Robb Knie, May2017 tarihinde atandı, in görev süresi 7.5 yıldır. in toplam yıllık tazminatı $ 868.82K olup, şirket hissesi ve opsiyonları dahil olmak üzere 51.8% maaş ve 48.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.84% ine doğrudan sahiptir ve bu hisseler $ 48.83K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.7 yıl ve 4.8 yıldır.

Anahtar bilgiler

Robb Knie

İcra Kurulu Başkanı

US$868.8k

Toplam tazminat

CEO maaş yüzdesi	51.8%
CEO görev süresi	7.5yrs
CEO sahipliği	0.8%
Yönetim ortalama görev süresi	5.7yrs
Yönetim Kurulu ortalama görev süresi	4.8yrs

Son yönetim güncellemeleri

Recent updates

Hoth Therapeutics partners with Altasciences to manufacture HT-TBI for brain injury

Sep 20

Hoth Therapeutics granted grace days by Nasdaq to regain compliance with bid price rule

Jun 29

Hoth Therapeutics shares rise 10% on developmental plans for HT-KIT in multiple orphan diseases and rare cancers

May 03

Hoth provides pipeline and regulatory timeline update

Feb 02

FDA grants Hoth Therapeutics Pre-IND meeting for HT-001, shares up 15%

Jan 13

Hoth Therapeutics to initiate IND enabling studies of HT-001 in cancer

Jan 11

Hoth Therapeutics inks deal for treatment of multi-drug resistant bacterial lung infections, shares up 15%

Jan 04

CEO Tazminat Analizi

Robb Knie'un ücretlendirmesi Hoth Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$8m
Jun 30 2024	n/a	n/a	-US$7m
Mar 31 2024	n/a	n/a	-US$8m
Dec 31 2023	US$869k	US$450k	-US$8m
Sep 30 2023	n/a	n/a	-US$10m
Jun 30 2023	n/a	n/a	-US$10m
Mar 31 2023	n/a	n/a	-US$11m
Dec 31 2022	US$1m	US$450k	-US$11m
Sep 30 2022	n/a	n/a	-US$11m
Jun 30 2022	n/a	n/a	-US$12m
Mar 31 2022	n/a	n/a	-US$13m
Dec 31 2021	US$1m	US$400k	-US$14m
Sep 30 2021	n/a	n/a	-US$12m
Jun 30 2021	n/a	n/a	-US$10m
Mar 31 2021	n/a	n/a	-US$10m
Dec 31 2020	US$781k	US$350k	-US$7m
Sep 30 2020	n/a	n/a	-US$10m
Jun 30 2020	n/a	n/a	-US$10m
Mar 31 2020	n/a	n/a	-US$9m
Dec 31 2019	US$2m	US$350k	-US$8m
Sep 30 2019	n/a	n/a	-US$4m
Jun 30 2019	n/a	n/a	-US$3m
Mar 31 2019	n/a	n/a	-US$3m
Dec 31 2018	US$308k	US$250k	-US$2m
Sep 30 2018	n/a	n/a	-US$3m
Dec 31 2017	US$146k	US$146k	-US$3m

Tazminat ve Piyasa: Robb 'nin toplam tazminatı ($USD 868.82K ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 647.72K ).

Tazminat ve Kazançlar: Robb 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Robb Knie (55 yo)

7.5yrs

Görev süresi

US$868,823

Tazminat

Mr. Robb Knie is Founder of Hoth Therapeutics, Inc. Mr. Knie served as the Chief Executive Officer, Chief Financial Officer and Chairman of the Board of Directors of FoxWayne Enterprises Acquisition Corp....

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Robb Knie	Founder	7.5yrs	US$868.82k	0.84% $ 48.8k
David Briones	Chief Financial Officer	5.7yrs	Veri yok	Veri yok
Hayley Springer	Executive Vice President of Operations	2.5yrs	Veri yok	Veri yok

5.7yrs

Ortalama Görev Süresi

Deneyimli Yönetim: HOTH 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.7 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Robb Knie	Founder	7.5yrs	US$868.82k	0.84% $ 48.8k
Adam Friedman	Member of Scientific Advisory Board	7.3yrs	Veri yok	Veri yok
Mario Lacouture	Member of Scientific Advisory Board	3.8yrs	Veri yok	Veri yok
David Sarnoff	Independent Director	6.3yrs	US$65.21k	0.014% $ 839.7
William Weglicki	Member of Scientific Advisory Board	4.9yrs	Veri yok	Veri yok
Wayne Linsley	Independent Director	4.6yrs	US$65.21k	0.0019% $ 112.5
Glenn Cruse	Member of Scientific Advisory Board	4.8yrs	Veri yok	Veri yok
Graig Springer	Independent Director	4.8yrs	US$65.21k	0.018% $ 1.0k
Sergio Traversa	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Jeff Pavell	Independent Director	1.9yrs	US$65.21k	0.074% $ 4.3k
John Cirrito	Member of Scientific Advisory Board	2.8yrs	Veri yok	Veri yok
Carla Yuede	Member of Scientific Advisory Board	2.8yrs	Veri yok	Veri yok

4.8yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: HOTH 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.8 yıldır).

Hoth Therapeutics Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Hoth Therapeutics, Inc., Annual General Meeting, Aug 07, 2024

Hoth Therapeutics, Inc., Annual General Meeting, Aug 18, 2023

Hoth Therapeutics, Inc. Announces Board Changes

High number of new and inexperienced directors

High number of new and inexperienced directors

Hoth Therapeutics, Inc. Announces Scientific Advisory Board Appointments

Recent updates

Hoth Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.7 million.

Hoth Therapeutics Notifies by the Nasdaq Regarding Not in Compliance with the Minimum Bid Price Requirements

Hoth Therapeutics, Inc. Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment Study

Hoth Therapeutics, Inc. Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ

New major risk - Share price stability

Price target decreased by 14% to US$4.50

New minor risk - Share price stability

Hoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment

Hoth Therapeutics, Inc. Expands Clinical Trial for Cancer Patients

New major risk - Shareholder dilution

Hoth Therapeutics, Inc., Annual General Meeting, Aug 07, 2024

New major risk - Financial position

Hoth Therapeutics, Inc. Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ

Hoth Therapeutics Receives FDA Approval to Expand HT-001 Clinical Trial to Treat Severely III Patients

Hoth Therapeutics Announces Expansion of FDA Cleared First-In-Human Clinical Trial for Cancer Patients of HT-001 At University of Miami

Hoth Therapeutics Announces Successfully Completed Manufacturing of its Cancer Fighting HT-KIT for Ind-Enabling Studies

Hoth Therapeutics, Inc. Announces Positive Results Killing Cancer Cells in Both Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia

Price target decreased by 50% to US$9.50

Hoth Therapeutics, Inc. Doses First Patient in its Phase 2a Clinical Trial of HT-001 for Treatment of Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors

Hoth Therapeutics, Inc. Receives Protocol Approval for HT-001 Cancer Therapeutic

Hoth Therapeutics Announces Irb Approval for Fda Cleared First-In-Human Clinical Trial of Ht-001 At Second Clinical Site

New major risk - Share price stability

Hoth Therapeutics, Inc., Annual General Meeting, Aug 18, 2023

Algorithm Sciences, Inc. cancelled the acquisition of Hoth Therapeutics, Inc. (NasdaqCM:HOTH) in a reverse merger transaction.

Hoth Therapeutics Announces Increased Positive Results of its Alzheimer's Therapeutic HT-ALZ

Hoth Therapeutics, Inc. Announces Selection of First 3 Clinical Sites for its Phase 2 Clinical Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy

Price target decreased to US$19.00

Hoth Therapeutics, Inc. announced that it expects to receive $10 million in funding

Hoth Therapeutics, Inc. Announces Board Changes

High number of new and inexperienced directors

Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements

Hoth Therapeutics Reports Positive Biolexa Phase 1B Clinical Trial Results in Mild to Moderate Atopic Dermatitis

Hoth Therapeutics Announces 1:25 Reverse Stock Split to Regain Compliance

Hoth Therapeutics partners with Altasciences to manufacture HT-TBI for brain injury

Hoth Therapeutics, Inc. mRNA Frame-Shifting Therapeutic, HT-004, Shows Potential to Reduce Lung Inflammation in Asthma and Allergy Disorders

Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Cognitive Improvements in Alzheimer's Disease Mouse Model

Hoth Therapeutics Gets 180 Grace Days by Nasdaq to Regain Compliance with Bid Price Rule

Hoth Therapeutics granted grace days by Nasdaq to regain compliance with bid price rule

Hoth Therapeutics, Inc, Announces HREC Approval in Australia for Next Phase of Trial of BioLexa for Patients with Atopic Dermatitis

Price target decreased to US$3.00

Hoth Therapeutics, Inc. Announces Preliminary Efficacy Findings From Phase 1b Clinical Trial with Mild to Moderate Atopic Dermatitis Patient Cohort

Price target decreased to US$3.50

High number of new and inexperienced directors

Hoth Therapeutics, Inc. Announces Development Updates for Its Novel Cancer Therapeutic, HT-KIT

Forecast to breakeven in 2023

Forecast to breakeven in 2023

Hoth Therapeutics Announces Presentation of the HT-ALZ Proof-of-Concept Alzheimer's Disease Preclinical Data at the 2022 Alzheimer's Association International Conference

Hoth Therapeutics, Inc. Announces Scientific Advisory Board Appointments

Hoth Therapeutics, Inc. Begins Dosing to Investigate the Effect of HT-ALZ on Memory, Anxiety, and Executive Function

Hoth Therapeutics, Inc. Announces HT-ALZ Therapeutic Shows Positive Results - Reduce Amyloid ß in Alzheimer's Disease

Hoth Therapeutics, Inc Announces Submission of Orphan Drug Designation Request for HT-KIT to Treat Mastocytosis

Hoth Therapeutics' Enrollment and Dosing in Second Cohort in Phase 1b Human Trial for Atopic Dermatitis Under Way

Price target decreased to US$4.75

Here's Why We're Watching Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Situation

Hoth Therapeutics, Inc. Submits to Ethics Committee for Approval to Initiate Patient Cohort 2 in BioLexa Clinical Trial

Hoth Therapeutics, Inc. Announces Positive Phase 1b Results for Completed First Cohort of Patient Trial of BioLexa

Price target decreased to US$7.25

Hoth Therapeutics, Inc. Initiates Preclinical Study of HT-ALZ for Alzheimer's Disease

Hoth Therapeutics, Inc. Announces Positive Confirmatory Results from in Vivo Model of Ht-003 Assets as Potential Treatment Against Acne

Hoth Therapeutics extends agreement for experimental antibiotic

We're Not Very Worried About Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Rate

Hoth Therapeutics Shares Positive Preclinical Results of Novel HT-KIT Therapeutic

Hoth Therapeutics Announces Development of HT-KIT to Treat Multiple Orphan Diseases, Including Rare Cancers

Hoth Therapeutics expands research agreement with VCU for COVID-19 therapeutic

Hoth Therapeutics shares rise 10% on developmental plans for HT-KIT in multiple orphan diseases and rare cancers

Hoth Therapeutics Executes Agreement to Assess the Effect of HT-003 Therapeutic Platform on Ulcerative Colitis and Crohn's Disease

Hoth Therapeutics, Inc. announced that it expects to receive $15.000001 million in funding

Hoth Therapeutics, Inc. Provides Update on Novel Peptide COVID-19 Therapeutic HT-002 Preclinical Studies

Hoth Therapeutics, Inc. Completes Site Recruitment for Cohort 1 of First in Human Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis